Economy

CVS to replace CEO Karen Lynch with long-time exec David Joyner

(Reuters) -CVS Health on Friday named company veteran David Joyner as new CEO, succeeding Karen Lynch who stepped down from the helm of the struggling healthcare giant after an agreement with the board.

Shares of the company tumbled 11% to $57 in premarket trading.

Joyner, who is the president of the company’s pharmacy benefit manager CVS Caremark, takes over as president and CEO from Friday, the company said.

The change comes on the back of repeated profit forecast cuts this year as the company’s insurance segment has struggled with rising medical costs.

“The board believes this is the right time to make a change, and we are confident that David is the right person to lead our company,” said Chairman Roger Farah.

The healthcare giant is also exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, Reuters reported earlier this week.

The Wall Street Journal had first reported the news of Joyner’s appointment on Friday.

This post appeared first on investing.com

You May Also Like

Editor's Pick

Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

Economy

LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

Editor's Pick

Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

Latest News

Warner Bros. Discovery said Thursday its streaming platform Max added 7.2 million global subscribers in the third quarter. It marked the biggest quarterly growth for...

Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 beneficialinvestmentnow.com

Exit mobile version